You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Designing and Using Antibody-Drug Conjugates to Treat Solid Tumors

  • Authors: Giuseppe Curigliano, MD, PhD; Pasi A. Jänne, MD, PhD; Jonathan E. Rosenberg, MD
  • CME / ABIM MOC Released: 4/28/2023
  • Valid for credit through: 4/28/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pathologists, and other members of the multidisciplinary care team.

The goal of this activity is for learners to be better able to understand the dynamic potential of ADC therapies in the treatment of patients with solid tumors.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of ADC therapy
    • Clinical trial data evaluating ADCs for the treatment of solid tumors
  • Have greater competence related to
    • Accurately identifying patients that would be eligible to receive ADCs for the treatment of solid tumors
    • Individualizing care for patients receiving ADCs for the treatment of solid tumors
  • Demonstrate greater confidence in their ability to
    • Incorporate emerging ADC data into the clinical care of patients with solid tumors


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Chair/Moderator

  • Giuseppe Curigliano, MD, PhD

    Professor of Medical Oncology 
    University of Milan 
    Director, Division of Early Drug Development Department, 
    European Institute of Oncology 
    Milan, Italy

    Disclosures

    Giuseppe Curigliano, MD, PhD, has the following relevant financial relationships: 
    Consultant or advisor for: AstraZeneca; Bristol Myers Squibb Company; Celcuity; Daiichi Sankyo; Gilead Sciences, Inc.; Lilly; Menarini; Merck & Co., Inc.; Novartis Pharmaceuticals; Roche; Sanofi; Seagen, Inc.
    Speaker or member of speakers bureau for: Daiichi Sankyo; Lilly
    Research funding from: Merck & Co., Inc.

Faculty/Panelist

  • Pasi A. Jänne, MD, PhD

    Professor of Medicine,
    Harvard Medical School
    Director, Lowe Center for Thoracic Oncology
    Dana- Farber Cancer Institute
    Boston, Massachusetts, United States

    Disclosures

    Pasi A. Jänne, MD, PhD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; Accutar Biotech; Allorion Therapeutics; AstraZeneca; Bayer; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Chugai Pharmaceuticals; Daiichi Sankyo; Eisai Inc.; Frontier Medicines; Hongyun Biotechnology; Lilly; Merus; Mirati Therapeutics; Monte Rosa Therapeutics; Novartis Pharmaceuticals; Nuvalent; Pfizer, Inc.; Roche/Genentech, Inc.; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals; Silicon Therapeutics; Syndax Pharmaceuticals, Inc.; Takeda Oncology; Transcenta; Voronoi
    Research funding from: Astellas Pharmaceuticals; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda Oncology
    Royalties from: LabCorp for patent licensed to LabCorp

  • Jonathan E. Rosenberg, MD

    Jonathan E. Rosenberg, MD 
    Chief, Genitourinary Oncology Service 
    Enno W. Ercklentz Chair 
    Memorial Sloan Kettering Cancer Center 
    New York, New York, United States

    Disclosures

    Jonathan E. Rosenberg, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Aadi Bioscience; Alligator Bioscience; Astellas Pharmaceuticals; AstraZeneca; Bicycle Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Century Therapeutics; EMD-Serono; Emergence Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; Hengrui; IMVax; Infinity; Merck & Co., Inc.; Mirati; Pfizer, Inc.; Paige.AI; QED Therapeutics; Seagen, Inc.; Tyra Biosciences
    Contracted researcher for: Astellas Pharmaceuticals; AstraZeneca; Acrivon; Bayer; Genentech, Inc.; QED Therapeutics; Seagen Inc.

Editor

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC 

    Disclosures

    Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Designing and Using Antibody-Drug Conjugates to Treat Solid Tumors

Authors: Giuseppe Curigliano, MD, PhD; Pasi A. Jänne, MD, PhD; Jonathan E. Rosenberg, MDFaculty and Disclosures

CME / ABIM MOC Released: 4/28/2023

Valid for credit through: 4/28/2024

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to understand the dynamic potential of antibody-drug conjugates therapies in the treatment of patients with solid tumors.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print